Wugen

Wugen is committed to developing off-the-shelf cell therapies for cancer treatment. These cell therapy drugs are derived from healthy donors and amplified to enhance the elimination of cancer cells. Our immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML), multiple myeloma (MM), and T-cell malignancies. We focus on off-the-shelf products: NK cell therapies targeting solid tumors, AML, and MM; CAR-T targeting T-cell malignancies; and CAR-T targeting AML cells while avoiding healthy stem cells.